Open AccessFluoropyrimidine‐Associated Cardiotoxicity: A Retrospective Case‐Control Study
Author(s) -
Raber Inbar,
Warack Sarah,
Kanduri Jaya,
Pribish Abby,
Godishala Anuradha,
Abovich Arielle,
Orbite Anna,
Dommaraju Sujithraj,
Frazer Morgan,
Peters Mary Linton,
Asnani Aarti
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2019-0762
Subject(s) - medicine , cardiotoxicity , capecitabine , coronary vasospasm , coronary artery disease , retrospective cohort study , cardiomyopathy , cardiology , heart failure , oncology , chemotherapy , angina , cancer , colorectal cancer , myocardial infarction
Background The fluoropyrimidines, 5‐fluorouracil (5‐FU) and capecitabine, are commonly used chemotherapeutic agents that have been associated with coronary vasospasm. Methods In this retrospective case‐control study, we identified patients at our institution who received 5‐FU or capecitabine in 2018. We compared characteristics of patients who experienced cardiotoxicity with controls. We described phenotypes and outcomes of cardiotoxic cases. Results We identified 177 patients who received fluoropyrimidines. After adjudication, 4.5% of the cohort met the criteria for cardiovascular toxicity. Coronary artery disease was more common among cases than controls (38% vs. 7%, p < .05). There was also a trend toward increased prevalence of cardiovascular risk factors in cases compared with controls. Most cardiotoxic cases had chest pain, although a minority of cases presented with nonischemic cardiomyopathy. Conclusion Cardiotoxicity phenotypes associated with fluoropyrimidine use are not limited to coronary vasospasm. Cardiac risk factors and ischemic heart disease were highly prevalent among patients with cardiotoxicity.